An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
In research, discovery yields innovation. At the Ted Rogers Centre, we know that successfully commercializing that innovation is critical to the goal of solving heart failure.
We must work to ensure each promising treatment, engineering solution and diagnostic method has a chance to reach the clinic so it can have clinical impact.
Our Centre cultivates, supports and enables innovations that have strong translational potential. We support the idea, assist with design and development, and move it along the path to commercialization: a deeply collaborative process connecting science to enterprise.
Translation & Commercialization Committee (TCC)
Early discovery must chart a course to translation. Our TCC is in place to review every funded project, categorize its IP and commercialization potential, and advise on how our Centre can enhance its value proposition and opportunity for impact.
While the Ted Rogers Centre funds discovery, we become the advocate of ensuring that any invention or IP developed is focused on cardiac care, and is poised for translation. Our deep collaborative networks ensure that an innovation is refined in such a way that positions it in the best way possible for commercialization.
Professor, Institute of Biomedical Engineering and Faculty of Dentistry, U of T Baxter Chair in Health Technology & Commercialization, UHN
Principal, Business Development and Commercialization, UHN
Senior Medical Advisor for Innovative Therapies, SickKids
Our Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program is designed to train innovators of cardiovascular technologies in bringing their technologies to market. As such, this experiential program is a key facet of how the Ted Rogers Centre translates innovation.
Each year, at least 10 de-novo cardiac companies run through ECHO, with winners of an annual pitch competition earning up to $250,000 in startup capital. ECHO is a pipeline of homegrown innovations through translation.
ECHO is unique in that it gives non-dilutive funds, asking for no share in a company – a concept that is forgiving to early-stage innovators. There are very few agencies in Canada willing to invest like this specifically in translating innovation.